If you have been reading about MC1R and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-04-30. Where a claim depends on a specific study, the study is described rather than over-claimed.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
The material is commonly handled as a lyophilized powder in sealed vials. The solid dissolves readily in water and in polar organic solvents, producing a clear solution after reconstitution. Light, heat and repeated freeze-thaw cycles are the concerns most often raised in handling guidance, because peptide bonds and the constrained ring can degrade. Working solutions are generally prepared fresh, and material left in solution is treated as less stable than the dry form. These properties shape how laboratories store and aliquot reference material.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry. Retention time supports identity, while the mass spectrum confirms the molecular weight of the intact peptide. Purity is frequently reported as a percentage of total peak area, a figure that depends on the wavelength, column and gradient used. Impurity profiling may also look for truncated sequences, oxidised forms and residual counterions. Amino acid analysis and peptide mapping provide orthogonal confirmation when required.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Belongs to the melanocortin agonist family |
| Key substitutions | Nle4 and D-Phe7 | Improve resistance to enzymatic degradation |
| Molecular formula | C50H69N15O9 | Approximately 1024 g/mol |
| Regulatory status | Not approved as a medicine | Distributed as a research chemical |
| Common synonyms | Melanotan II, MT-II, MT-2 | Spelling varies across sources |
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Melanotan II holds no marketing authorisation from the Food and Drug Administration, the European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency or Australia's Therapeutic Goods Administration. Products sold under that name are treated as unapproved new drugs, and their sale or import is prohibited in several jurisdictions. Other countries classify the peptide as a prescription-only medicine or place it among controlled substances, so the legal position changes with the destination market. No pharmacopoeial monograph supplies an official specification, because the material is not a licensed pharmaceutical. Consequently, products offered online are not manufactured to a shared public standard.
The peer-reviewed record is dominated by small early-phase studies, case reports and pharmacovigilance summaries rather than large randomised trials. Papers typically examine tanning response, receptor selectivity or patterns of reported adverse events. Many note that participants obtained the peptide outside a clinical setting, which limits verification of composition and administered amount. Reported events vary widely, and causality is frequently unclear because the identity and purity of self-sourced material are unknown. Open questions include whether repeated melanocortin receptor stimulation produces cumulative effects, and how often label claims match actual content.
The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.
Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.
Commodore Tim Hare, former Director of Nuclear Policy at the British Ministry of Defence, has described "sub-strategic use" as offering the Government "an extra option in the escalatory process before it goes for an all-out strategic strike which would deliver unacceptable damage". However, this sub-strategic capacity has been criticized as potentially increasing the "acceptability" of using nuclear weapons. Combined with the trend in the reduction in the worldwide nuclear arsenal as of 2007 is the warhead miniaturization and modernization of the remaining strategic weapons that is presently occurring in all the declared nuclear weapon states, into more "usable" configurations. The Stockholm International Peace Research Institute suggests that this is creating a culture where use of these weapons is more acceptable and therefore is increasing the risk of war, as these modern weapons do not possess the same psychological deterrent value as the large Cold-War era, multi-megaton warheads. In many ways, this present change in the balance of terror can be seen as the complete embracement of the switch from the 1950s Eisenhower doctrine of "massive retaliation" to one of "flexible response", which has been growing in importance in the US nuclear war fighting plan/SIOP every decade since. For example, the United States adopted a policy in 1996 of allowing the targeting of its nuclear weapons at non-state actors ("terrorists") armed with weapons of mass destruction.
In 2010 ISB partnered with the Ohio State University Wexner Medical Center in Columbus, Ohio, to establish the nonprofit P4 Medicine Institute (P4MI). Its goal was stated as being "to lead the transformation of healthcare from a reactive system to one that predicts and prevents disease, tailors diagnosis and therapy to the individual consumer and engages patients in the active pursuit of a quantified understanding of wellness; i.e. one that is predictive, preventive, personalized and participatory (P4)." In 2012, P4 Medical Institute established an agreement with its first community health partner, PeaceHealth. PeaceHealth is a not-for-profit Catholic health care system, operating in a variety of communities in Alaska, Washington and Oregon. In 2016, ISB affiliated with Providence Health & Services, and Hood became the senior vice president of Providence St. Joseph Health and its chief science officer. Hood has published more than 700 peer-reviewed papers, received 36 patents, and co-authored textbooks in biochemistry, immunology, molecular biology, and genetics. In addition, he co-authored, with Daniel J. Kevles, The Code of Codes, a popular book on the sequencing of the human genome. He has been instrumental in founding 15 biotechnology companies, including Amgen, Applied Biosystems, Systemix, Darwin, Rosetta Inpharmatics, Integrated Diagnostics, and Accelerator Corporation. In 2015, he co-founded a startup called Arivale offering a subscription-based 'scientific wellness' service which shut down in 2019.
The gallbladder is a hollow part of the biliary tract that sits just beneath the liver, with the gallbladder body resting in a small depression. It is a small organ where the bile produced by the liver is stored, before being released into the small intestine. Bile flows from the liver through the bile ducts and into the gall bladder for storage. The bile is released in response to cholecystokinin (CCK), a peptide hormone released from the duodenum. The production of CCK (by endocrine cells of the duodenum) is stimulated by the presence of fat in the duodenum. It is divided into three sections, a fundus, body and neck. The neck tapers and connects to the biliary tract via the cystic duct, which then joins the common hepatic duct to form the common bile duct. At this junction is a mucosal fold called Hartmann's pouch, where gallstones commonly get stuck. The muscular layer of the body is of smooth muscle tissue that helps the gallbladder contract, so that it can discharge its bile into the bile duct. The gallbladder needs to store bile in a natural, semi-liquid form at all times. Hydrogen ions secreted from the inner lining of the gallbladder keep the bile acidic enough to prevent hardening. To dilute the bile, water and electrolytes from the digestion system are added. Also, salts attach themselves to cholesterol molecules in the bile to keep them from crystallising. If there is too much cholesterol or bilirubin in the bile, or if the gallbladder does not empty properly the systems can fail.
Sources: en.wikipedia.org
Renal corpuscle: Liquid enters the nephron system at the Bowman's capsule. Proximal convoluted tubule: It then may reabsorb urea in the thick descending limb. Water is removed from the nephrons by osmosis (and glucose and other ions are pumped out with active transport), gradually raising the concentration in the nephrons. Loop of Henle Descending: The liquid passes from the thin descending limb to the thick ascending limb. Water is constantly released via osmosis. Gradually there is a buildup of osmotic concentration, until 1200 mOsm is reached at the loop tip, but the difference across the membrane is kept small and constant. For example, the liquid at one section inside the thin descending limb is at 400 mOsm while outside it is 401. Further down the descending limb, the inside concentration is 500 while outside it is 501, so a constant difference of 1 mOsm is kept all across the membrane, although the concentration inside and outside are gradually increasing. Loop of Henle Ascending: after the tip (or 'bend') of the loop, the liquid flows in the thin ascending limb. Salt–sodium Na+ and chloride Cl− ions are pumped out of the liquid gradually lowering the concentration in the exiting liquid, but, using the countercurrent multiplier mechanism, always pumping against a constant and small osmotic difference. For example, the pumps at a section close to the bend, pump out from 1000 mOsm inside the ascending limb to 1200 mOsm outside it, with a 200 mOsm across.
The first column specifies the position, the second column contains the number of occurrences of A at that position, the third column contains the number of occurrences of C at that position, the fourth column contains the number of occurrences of G at that position, the fifth column contains the number of occurrences of T at that position, and the last column contains the IUPAC notation for that position. Note that the sums of occurrences for A, C, G, and T for each row should be equal because the PFM is derived from aggregating several consensus sequences.
For the US, the very concept of self-defending bombers was called into question, but instead of abandoning daylight raids and turning to night bombing, as the RAF suggested, they chose other paths; at first, bombers converted to gunships (the Boeing YB-40) were believed to be able to escort the bomber formations, but when the concept proved to be unsuccessful, thoughts then turned to the Lockheed P-38 Lightning. In early 1943, the USAAF also decided that the Republic P-47 Thunderbolt and P-51B be considered for the roles of smaller escort fighters, and in July, a report stated that the P-51B was "the most promising plane" with an endurance of 4 hours 45 minutes with the standard internal fuel of 184 US gallons (700 L) plus 150 US gallons (570 L) carried externally. In August, a P-51B was fitted with an extra internal 184-US-gallon (700 L) tank, but problems with longitudinal stability occurred, so some compromises in performance with the full tank were made. Since the fuel from the fuselage tank was used during the initial stages of a mission, the fuel tank would be fitted in all Mustangs destined for VIII Fighter Command.
Sources: en.wikipedia.org
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.
No regulatory agency has approved it for any indication. It is encountered as a research chemical sold outside pharmaceutical supply chains. Products marketed this way are not subject to the manufacturing and labeling requirements that apply to approved drugs.
Reports describe increased skin pigmentation as well as side effects such as nausea, flushing, and changes to existing moles. Much of the evidence comes from small studies and case reports rather than large trials. The long-term safety profile is therefore uncertain.
The dry powder is more stable during transport and storage than a solution. It also allows a known amount of material to be reconstituted at a chosen concentration.